ID26254A - Komposisi farmasi yang terdiri dari satu gabungan antara metformin dan fibrate, dan penggunaannya dalam penyiapan obat-obatan yang ditujukan untuk menurukan hiperglikaemia - Google Patents

Komposisi farmasi yang terdiri dari satu gabungan antara metformin dan fibrate, dan penggunaannya dalam penyiapan obat-obatan yang ditujukan untuk menurukan hiperglikaemia

Info

Publication number
ID26254A
ID26254A IDW20001765A ID20001765A ID26254A ID 26254 A ID26254 A ID 26254A ID W20001765 A IDW20001765 A ID W20001765A ID 20001765 A ID20001765 A ID 20001765A ID 26254 A ID26254 A ID 26254A
Authority
ID
Indonesia
Prior art keywords
towarded
hyperglicemia
fibrate
metformin
join
Prior art date
Application number
IDW20001765A
Other languages
English (en)
Indonesian (id)
Inventor
Yves Bonhomme
Philippe Briet
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of ID26254A publication Critical patent/ID26254A/id

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IDW20001765A 1998-02-12 1999-01-30 Komposisi farmasi yang terdiri dari satu gabungan antara metformin dan fibrate, dan penggunaannya dalam penyiapan obat-obatan yang ditujukan untuk menurukan hiperglikaemia ID26254A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9801709A FR2774591B1 (fr) 1998-02-12 1998-02-12 Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie

Publications (1)

Publication Number Publication Date
ID26254A true ID26254A (id) 2000-12-07

Family

ID=9522912

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20001765A ID26254A (id) 1998-02-12 1999-01-30 Komposisi farmasi yang terdiri dari satu gabungan antara metformin dan fibrate, dan penggunaannya dalam penyiapan obat-obatan yang ditujukan untuk menurukan hiperglikaemia

Country Status (28)

Country Link
US (1) US6372790B1 (zh)
EP (1) EP1054665B1 (zh)
JP (1) JP4767411B2 (zh)
KR (1) KR100567608B1 (zh)
CN (1) CN1151785C (zh)
AR (1) AR018286A1 (zh)
AT (1) ATE204754T1 (zh)
AU (1) AU746821B2 (zh)
BR (1) BRPI9907866B8 (zh)
CA (1) CA2320039C (zh)
CZ (1) CZ290101B6 (zh)
DE (1) DE69900249T2 (zh)
DK (1) DK1054665T3 (zh)
ES (1) ES2162517T3 (zh)
FR (1) FR2774591B1 (zh)
HK (1) HK1034913A1 (zh)
HU (1) HU224619B1 (zh)
ID (1) ID26254A (zh)
MY (1) MY118164A (zh)
NO (1) NO328314B1 (zh)
PL (1) PL196874B1 (zh)
PT (1) PT1054665E (zh)
RU (1) RU2207850C2 (zh)
SK (1) SK283212B6 (zh)
TW (1) TW518222B (zh)
UA (1) UA70315C2 (zh)
WO (1) WO1999040904A2 (zh)
ZA (1) ZA991077B (zh)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4278863B2 (ja) * 1997-12-08 2009-06-17 ブリストル−マイヤーズ スクイブ カンパニー メトホルミンの新規塩および方法
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
FR2796551B1 (fr) * 1999-07-23 2003-07-25 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
FR2796940B1 (fr) * 1999-07-26 2005-04-08 Lipha Nouveaux sels de metformine, leur procede d'obtention et les compositions pharmaceutiques en renfermant
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US7151191B2 (en) * 2000-01-13 2006-12-19 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6531158B1 (en) * 2000-08-09 2003-03-11 Impax Laboratories, Inc. Drug delivery system for enhanced bioavailability of hydrophobic active ingredients
JP4829411B2 (ja) * 2001-02-23 2011-12-07 キッセイ薬品工業株式会社 Ｃ型慢性肝炎治療剤
GB0119480D0 (en) 2001-08-09 2001-10-03 Jagotec Ag Novel compositions
KR100897890B1 (ko) 2002-06-17 2009-05-18 인벤티아 헬스케어 피브이티. 엘티디. 티아졸리딘디온 및 바이구아나이드를 함유하는 다층 정제및 그의 제조 방법
EP1424070A1 (en) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Combination of a PPAR alpha agonist and metformin for decreasing the serum triglycerides
CA2509101A1 (en) 2002-12-13 2004-07-01 Jagotec Ag A topical nanoparticulate spironolactone formulation
FR2851734B1 (fr) * 2003-02-28 2006-06-09 Galenix Innovations Procede pour la fabrication d'une composition pharmaceutique sous la forme de comprimes contenant un fibrate et comprimes obtenus selon le procede
FR2858556B1 (fr) * 2003-08-06 2006-03-10 Galenix Innovations Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
US8062664B2 (en) * 2003-11-12 2011-11-22 Abbott Laboratories Process for preparing formulations of lipid-regulating drugs
TWI350751B (en) 2003-12-19 2011-10-21 Omega Bio Pharma Ip3 Ltd Pharmaceutical compositions for treating diabetes
EP1559419A1 (en) * 2004-01-23 2005-08-03 Fournier Laboratories Ireland Limited Pharmaceutical formulations comprising metformin and a fibrate, and processes for their obtention
US20070197602A1 (en) * 2004-02-09 2007-08-23 Hashime Kanazawa Combined pharmaceutical composition
EP1591114A1 (en) * 2004-03-12 2005-11-02 Fournier Laboratories Ireland Limited Use of metformin and orlistat for the treatment or prevention of obesity
US20060286182A1 (en) * 2005-06-21 2006-12-21 Abeille Pharmaceuticals, Inc. Synergistic cinnamon combinations and methods for enhancing insulin activity
GB0602639D0 (en) * 2006-02-09 2006-03-22 Novartis Ag Organic compounds
US20090318496A1 (en) 2006-08-04 2009-12-24 Aska Pharmaceutical Co., Ltd. Preparation containing fibrate agent and process for producing the same
CN101342164B (zh) * 2007-08-21 2011-04-20 阜新市仙鹤制药有限责任公司 苯扎贝特控释制剂及其制备方法
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
ES2344183B1 (es) * 2009-02-18 2011-06-10 Italfarmaco, S.A. Uso de agentes sensibilizantes a insulina por via vaginal.
US9339458B2 (en) * 2009-02-18 2016-05-17 Itf Research Pharma, S.L.U. Use of vaginal insulin sensitizing agents
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
JP2015523382A (ja) * 2012-07-10 2015-08-13 テティス・ファーマシューティカルズ・エルエルシー メトホルミンの三塩形態
US8765811B2 (en) * 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) * 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
WO2015171516A1 (en) 2014-05-05 2015-11-12 Thetis Pharmaceuticals Llc Compositions and methods relating to ionic salts of peptides
US10166246B2 (en) 2014-05-27 2019-01-01 City Of Hope TGR5 agonist complexes for treating diabetes and cancer
MX2016016830A (es) 2014-06-18 2017-07-07 Thetis Pharmaceuticals Llc Complejos de aminoacidos minerales de agentes activos.
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
FR3050112B1 (fr) * 2016-04-15 2020-09-04 Soc Civ Immobiliere Gecinq Utilisation de l'acide fenofibrique dans le traitement des maladies hepatiques
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
US10344002B2 (en) 2016-09-26 2019-07-09 Nusirt Sciences, Inc. Compositions and methods for treating metabolic disorders
FR3056908B1 (fr) * 2016-09-30 2019-04-19 Nashpharm Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
JP2020503269A (ja) 2016-11-28 2020-01-30 リポカイン インコーポレーテッド 経口ウンデカン酸テストステロン療法
GB2599950A (en) * 2020-10-16 2022-04-20 Zentiva Ks Pharmaceutical compositions with low amounts of nitrosamine impurities and methods for producing the same
WO2023119100A1 (en) * 2021-12-22 2023-06-29 Mankind Pharma Ltd. Stable pharmaceutical compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2264525B1 (zh) * 1974-03-22 1977-11-04 Expl Marques Brevets Et
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
DE3729209A1 (de) * 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
JP3852621B2 (ja) * 1992-01-21 2006-12-06 あすか製薬株式会社 血管内皮細胞機能改善剤
EP0930882A2 (en) * 1996-08-02 1999-07-28 Institut Pasteur De Lille Prevention or treatment of type 2 diabetes or cardiovascular disease with ppar modulators

Also Published As

Publication number Publication date
DE69900249D1 (de) 2001-10-04
PL342665A1 (en) 2001-07-02
HK1034913A1 (en) 2001-11-09
AU746821B2 (en) 2002-05-02
ES2162517T3 (es) 2001-12-16
WO1999040904A3 (en) 1999-09-30
TW518222B (en) 2003-01-21
NO328314B1 (no) 2010-01-25
NO20004056L (no) 2000-08-11
CN1151785C (zh) 2004-06-02
EP1054665A2 (en) 2000-11-29
CN1290160A (zh) 2001-04-04
EP1054665B1 (en) 2001-08-29
KR100567608B1 (ko) 2006-04-04
BRPI9907866B8 (pt) 2021-05-25
JP4767411B2 (ja) 2011-09-07
CZ20002828A3 (cs) 2000-11-15
CA2320039A1 (en) 1999-08-19
HUP0100801A3 (en) 2001-12-28
PL196874B1 (pl) 2008-02-29
ZA991077B (en) 1999-08-11
CA2320039C (en) 2008-07-22
AU2923399A (en) 1999-08-30
HU224619B1 (hu) 2005-11-28
CZ290101B6 (cs) 2002-05-15
MY118164A (en) 2004-09-30
NO20004056D0 (no) 2000-08-11
DE69900249T2 (de) 2002-06-13
WO1999040904A2 (en) 1999-08-19
UA70315C2 (en) 2004-10-15
RU2207850C2 (ru) 2003-07-10
FR2774591B1 (fr) 2000-05-05
FR2774591A1 (fr) 1999-08-13
US6372790B1 (en) 2002-04-16
JP2002502869A (ja) 2002-01-29
ATE204754T1 (de) 2001-09-15
DK1054665T3 (da) 2001-12-27
HUP0100801A2 (hu) 2001-08-28
AR018286A1 (es) 2001-11-14
BR9907866A (pt) 2000-10-31
KR20010040925A (ko) 2001-05-15
SK283212B6 (sk) 2003-03-04
BRPI9907866B1 (pt) 2017-08-15
SK11562000A3 (sk) 2000-12-11
PT1054665E (pt) 2002-02-28

Similar Documents

Publication Publication Date Title
ID26254A (id) Komposisi farmasi yang terdiri dari satu gabungan antara metformin dan fibrate, dan penggunaannya dalam penyiapan obat-obatan yang ditujukan untuk menurukan hiperglikaemia
HUP0103752A3 (en) N,n-disubstituted amides and pharmaceutical compositions containing them that inhibit the binding of integrins to their receptors
ID23789A (id) Turunan-turunan amida heteroaril-heksanoat, pembuatannya dan penggunaannya sebagai penghambat selektif dari mip-1, alfa yang diikat ke reseptor ccr1-nya
ID26945A (id) Komposisi farmasi yang mengandung misel yang terdiri dari glukokortikosteroid lipofilik dan hanya satu surfaktan
BR9913751B1 (pt) uso de uma composiÇço para proteÇço do tecido, e, mÉtodo de tratar tecido para aperfeiÇoar a sua estabilidade dimensional.
ID23673A (id) Formulasi farmasi yang terdiri dari amoksicilin dan klavulanat
ID20586A (id) Skeloroglukan baru dan komposisi kosmetik yang mengandung senyawa baru
EE05183B1 (et) Asabitsklilised hendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon
AR026046A1 (es) NUEVA COMPOSICIoN Y MÉTODO PARA ESTABILIZAR LA MISMA
ID25784A (id) Bentuk dosis oral padat yang terdiri dari suatu kombinasi metformin dan glibernclamida
EE9700031A (et) Pürido-liitunud tienüül- ja furanüüloksasolidinoonid, nende valmistamismeetod, kasutamine ravimite valmistamiseks ja nimetatud ühendeid sisaldavad ravimid
AR009356A1 (es) Compuesto de 1-4 heterociclico, inhibidor de la metaloproteasa y su uso para preparar una composicion farmaceutica y para prevenir o tratar una enfermedad asociada con la actividad de la metalo proteasa y la caquexia
DE69710612D1 (de) Zeolith des im-5 -typs, dessen herstellung und katalytische verwendungen
PL322723A1 (en) Substituted 1-phenypyrazole-3-carboxyamides as active substances in respect to neurotensin rceptors, their production and pharmaceutic compositions containing them
DE60015893D1 (de) Zusammensetzung enthaltend ein carnitine und glutathion, zur erhöhung der absorption von glutathion und zur synergisierung seiner effekte
IL133883A0 (en) Directed cytolysis of target cells, agents and compositions causing cytolysis, and compounds that can be used to produce the agents
HUP0105313A3 (en) Potassium salt of (s)-omeprazole, process for its preparation and pharmaceutical composition containing the same and its use
HUP9903216A3 (en) Substituted benzamide and use of them as active ingredient in pharmaceutical compositions
HUP0202184A3 (en) Propanoic acid derivatives that inhibit the binding of integrins to their receptors, pharmaceutical compositions containing them and their use
ID29248A (id) Komposisi wujud padat yang terdiri dari partikel-partikel padat dan pengikatnya
ID26955A (id) Komposisi farmasi homogen yang terdiri dari abacavir, lamivudin dan zidovudin
IT1289581B1 (it) Miscela,composizione per la protezione delle piante contenente la miscela e suo impiego
MX9505181A (es) Utilizacion de un antagonista de la substancia p en una composicion farmaceutica para tratar desordenes de la piel de origen neurogenico.
FR2809957B1 (fr) Utilisation de particules de gel cubique comme agent anti-pollution, notamment dans une composition cosmetique
IS6378A (is) Efnasambönd og samsetningar gegn dvergveirum, notkun þeirra til lyfjagerðar og efni til að framleiða þau